Day: December 4, 2018

Lexington, Mass. – December 3, 2018

From Startup Kaleido Link to Full Article: Lexington, Mass. – December 3, 2018 – Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of Katharine Knobil, M.D., as chief medical officer (CMO) and head of research

ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting

From Startup ARQULE Link to Full Article: -ARQ 531 demonstrates anti-tumor activity and favorable safety profile -Dose escalation to continue – Call with management scheduled for 12/3 at 9:00 ET to discuss the results BURLINGTON, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from the Company’s